206 related articles for article (PubMed ID: 32346606)
1.
Liu Q; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
Mol Ther Oncolytics; 2020 Jun; 17():153-168. PubMed ID: 32346606
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening.
Sari S; Tomek P; Leung E; Reynisson J
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795096
[TBL] [Abstract][Full Text] [Related]
3. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
[TBL] [Abstract][Full Text] [Related]
4. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract][Full Text] [Related]
5. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of L- and D-5-[
Tang T; Gill HS; Ogasawara A; Tinianow JN; Vanderbilt AN; Williams SP; Hatzivassiliou G; White S; Sandoval W; DeMent K; Wong M; Marik J
Nucl Med Biol; 2017 Aug; 51():10-17. PubMed ID: 28511073
[TBL] [Abstract][Full Text] [Related]
7. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma.
Zhang S; Gao Y; Wang P; Wang S; Wang Y; Li M; Wang A; Zhao K; Zhang Z; Sun J; Guo D; Liang Z
Cancer Med; 2023 Dec; 12(24):21996-22005. PubMed ID: 38062922
[TBL] [Abstract][Full Text] [Related]
9. Parallel discovery of selective and dual inhibitors of tryptophan dioxygenases IDO1 and TDO2 with a newly-modified enzymatic assay.
Capochiani de Iudicibus R; Tomek P; Palmer BD; Tijono SM; Flanagan JU; Ching LM
Bioorg Med Chem; 2021 Jun; 39():116160. PubMed ID: 33901770
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.
Wu C; Spector SA; Theodoropoulos G; Nguyen DJM; Kim EY; Garcia A; Savaraj N; Lim DC; Paul A; Feun LG; Bickerdike M; Wangpaichitr M
Cancer Metab; 2023 May; 11(1):7. PubMed ID: 37226257
[TBL] [Abstract][Full Text] [Related]
11. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells.
Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
[TBL] [Abstract][Full Text] [Related]
12. Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function.
Too LK; Li KM; Suarna C; Maghzal GJ; Stocker R; McGregor IS; Hunt NH
Behav Brain Res; 2016 Oct; 312():102-17. PubMed ID: 27316339
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory Factors Galectin-9 and Interferon-Gamma Synergize to Induce Expression of Rate-Limiting Enzymes of the
Brooks AK; Lawson MA; Rytych JL; Yu KC; Janda TM; Steelman AJ; McCusker RH
Front Immunol; 2016; 7():422. PubMed ID: 27799931
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan catabolism is dysregulated in leiomyomas.
Chuang TD; Quintanilla D; Boos D; Khorram O
Fertil Steril; 2021 Oct; 116(4):1160-1171. PubMed ID: 34116832
[TBL] [Abstract][Full Text] [Related]
15. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel IDO1/TDO2 dual inhibitors: a consensus Virtual screening approach with molecular dynamics simulations, and binding free energy analysis.
Hanif N; Sari S
J Biomol Struct Dyn; 2024 Mar; ():1-17. PubMed ID: 38498355
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of indoleamine and tryptophan dioxygenases and three long non-coding RNAs in breast cancer.
Ghafouri-Fard S; Taherian-Esfahani Z; Dashti S; Kholghi Oskooei V; Taheri M; Samsami M
Exp Mol Pathol; 2020 Jun; 114():104415. PubMed ID: 32165090
[TBL] [Abstract][Full Text] [Related]
19. KYNU-related transcriptome profile and clinical outcome from 2994 breast tumors.
Li Y; Wang M; Zhao L; Liang C; Li W
Heliyon; 2023 Jun; 9(6):e17216. PubMed ID: 37383199
[TBL] [Abstract][Full Text] [Related]
20. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.
Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW
Front Immunol; 2020; 11():657. PubMed ID: 32477324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
